Institutional members access full text with Ovid®

Share this article on:

Purpuric Drug Eruption Secondary to Fidaxomicin

Mucci, Tania MD,; Davis-Lorton, Mark MD

Infectious Diseases in Clinical Practice: January 2014 - Volume 22 - Issue 1 - p e3–e4
doi: 10.1097/IPC.0b013e318281d8d7
Case Reports

Fidaxomicin is a recently Food and Drug Administration–approved oral medication for the treatment of Clostridium difficile infection. This medication is typically reserved for patients who have failed therapy with oral metronidazole. Here we present a case of a 79-year-old man with recurrent C. difficile infection who developed pitting lower extremity edema and a confluent, purpuric drug eruption 3 days into treatment with fidaxomicin. The rash improved completely with cessation of the medication. To our knowledge, this is the first report of a purpuric drug eruption secondary to fidaxomicin.

From the Section of Allergy and Immunology, Winthrop University Hospital, Mineola, NY.

Correspondence to: Tania Mucci, MD, Section of Allergy and Immunology, Winthrop University Hospital, 120 Mineola Blvd Suite 410, Mineola, NY 11501. E-mail: Tmucci@winthrop.org.

The authors have no funding or conflicts of interest to disclose.

© 2014 Wolters Kluwer Health, Inc. All rights reserved.